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Abstract 
Bryostatin 1, a macrocyclic lactone, has undergone phase I trials as an anticancer agent. Because of the lipid solubility of this 
compound it must be delivered either in ethanol or in a PET formulation. During the triM, these vehicles caused a large number of 
treatment-related si e effects. We have synthesized the triethanolamine salt of 26-succinylbryostatin 1 and find that this compound is
approx. 100-fold more water soluble than bryostatin 1. Because of the potential for clinical use, we have evaluated the biologic activity of 
this compound. We find that in a concentration-dependent ma ner 26-succinylbryostatin 1 s capable of activating protein kinase C (PKC) 
in vitro and displacing [3H]PDBu from PKC. However, at all concentrations tested the activity was less than the parent compound 
bryostatin 1. Addition of bryostatin 1 but not 26-succinylbryostatin 1 to U937 leukemic ells in culture stimulated a drop in cytosolic 
PKC, secondary to translocation of PKC to the membrane. Although 26-succinylbryostatin 1 did not stimulate a drop in the cytosolic 
levels of PKC, addition to U937 cells activated transcription from an AP-1 enhancer construct and c-Jun protein phosphorylation in a 
similar fashion to bryostatin 1 and differentiation of U937 cells. Unlike bryostatin 1, 26-succinylbryostatin 1 was unable to cause 
aggregation ofhuman platelets. Although injection of bryostatin-1 into mice carrying B 16 melanoma inhibits tumor growth, there was no 
significant inhibition of melanoma growth when identical doses of 26-succinyibryostatin 1 were injected. Therefore, 26-succinylbryostatin 
1 shares some but not all of the pharmacologic properities of bryostatin 1. This compound can activate protein phosphorylation without 
lowering cytosolic levels of PKC. 
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1. Introduction 
Bryostatin 1, a naturally occurring macrocyclic lactone 
derived from a marine bryozoan, Bugula neritina [1] ex- 
hibits both in vitro and in vivo anticancer activity. The 
cellular basis for the antitumor effects of this compound is 
unknown; however, an initial event in the mechanism of 
action of bryostatin 1 is activation of PKC [2]. Treatment 
of cells with bryostatin 1 activates PKC stimulating phos- 
phorylation of proteins, causing the translocation of PKC 
to the membrane and leading to the eventual degradation 
of PKC [3]. However, bryostatin 1 does not affect all PKC 
isoforms in an equivalent fashion [4]. Although it induces 
the translocation of or, ~, and e isoforms, the et isoform is 
degraded much more rapidly [5]. 
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In mice the administration of bryostatin 1 blocks the 
growth of P388 [6], B16 melanoma [7], and L10A B-cell 
lymphoma [8]. Although Bryostatin 1 inhibits clongenic 
growth of K562 cells (a myeloid cell line), REH cells (a 
pre B-lymphoblastic cell line), and fresh acute nonlympho- 
cytic leukemia cells, it shows only mariginal activity 
against clonogenic CEM cells (a T-lymphoblastic cell line) 
[9]. Although, bryostatin 1 stimulates the activity of PKC, 
other potential mechanisms for the antitumor activity of 
this agent have been considered [10]. In humans bryostatin 
1 stimulates the release of TNFct and IL-6, suggesting that 
cytokine release could play a role in this compound's 
antitumor activity [11]. Because, bryostatin 1 has been 
shown to trigger the development of cytotoxic T lympho- 
cytes [12,13] , these expanded T lymphocytes have been 
used in a protocol of adoptive antitumor immunity [14]. 
Two phase I trims of this agent have been carried out in 
humans [11,15]. The major side effect and dose limiting 
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toxicity of bryostatin 1 was muscle aches and joint pains 
which were not associated with any abnormality on EMG 
or elevation of creatinine phosphokinase. In addition, a 
transient and immediate fall in platelet and WBC count 
was also seen, but both of these levels returned to normal 
in a matter of days. The infusion of bryostatin 1 in 60% 
ethanol caused venous sclerosis, therefore the adminstra- 
tion of bryostatin 1 in this vehicle was stopped. The 
compound was then delivered in polyethylene glycol, 
ethanol, and Tween 80 (PET 60 /30 /10  v/v) .  Six patients 
receiving this formulation experienced skin flushing, dysp- 
nea, hypotension, and bradycardia which was thought o be 
secondary to the vehicle and not to bryostatin 1. Therefore, 
the lack of aqueous solubility of bryostatin 1 caused 
significant patient delivery problems. 
In the process of developing antibodies to bryostatin 1, 
we synthesized the triethanolamine salt of 26-suc- 
cinylbryostatin 1, which was found to have greatly in- 
creased solubility in aqueous olutions when compared to 
bryostatin 1. Because of the potential clinical utility of 
26-succinylbryostatin 1, we have evaluated its biological 
activity in in vitro assays, after addition to cells in tissue 
culture, and in an animal tumor model. Our studies demon- 
strate that while in some tissue culture assays 26-suc- 
cinylbryostatin 1 has similar biological activity to bryo- 
statin I, in animals bryostatin 1 is more potent than 
26-succinylbryostatin 1 as an antitumor agent. 
2. Materials and methods 
2.1. Chemicals and reagents 
Bryostatin 1 was provided by Dr. Kenneth Snader of 
the Drug Synthesis and Chemistry Branch, Developmental 
Therapeutics Program, Division of Cancer Treatment, Na- 
tional Cancer Institute, Bethesda, MD. Both bryostatin 1 
and succinylbryostatin 1 were stored at -20°C in 100% 
DMSO. Both compounds were diluted to 0.1% DMSO 
upon addition to tissue culture medium. All control experi- 
ments were done with the addition of identical amounts of 
DMSO. 
2.2. PKC assay and Western blot 
U937 cells obtained from the ATCC were grown in 
DMEM medium containing 10% iron-supplemented bovine 
calf serum, antibiotics, and 4 mM glutamine in a 5% 
CO2-humidified atmosphere. Cells were pelleted and 
washed twice with PBS. PKC assays were carried out as 
previously described using 100 I~M [~/-32p]ATP (~ 60 
cpm/pmol) [2,3]. To assay membrane bound PKC, after 
treatment with 26-succinylbryostatin 1 or bryostatin 1, 
cells were pelleted, washed, and sonicated [2,3]. The soni- 
cate was spun in an ultracentrifuge at 200 000 X g for 30 
min. The pellet was extracted with 1% Triton X-100, the 
extract placed over a DEAE-cellulose column, and PKC 
eluted as previously described [41]. Both the eluate and 
supernatant from the ultracentrifugation were assayed for 
PKC activity [2,3]. 
Western blots of PKC were done on both the super- 
natant and the pellet as described above. Approx. 300 Ixg 
of protein were loaded on a 8% SDS-PAGE gel and then 
transferred to nitrocellulose. Blots were blocked with 2% 
BSA in Tris-buffered saline, pH 7.6, for 1 h. These were 
then incubated with antiprotein kinase C antibody to PKC 
(Santa Cruz Biotechnology, Santa Cruz, CA) After 
incubation the western blot was washed with Tris-buffered 
saline (pH 7.6) containing (0.1% Tween-20) followed by 
incubation with a secondary antibody and the antigen/an- 
tibody complex detected by ECL (Amersham Life Sci- 
ences, Arlington Heights, I1). 
2.3. Competition assay for PKC binding 
A GST fusion protein containing amino acids 92-173 
of PKC [GST-Cys2 (92-173)] (a gift of Dr. R. Bell) was 
grown and purified as described [16,17]. To evaluate the 
ability of bryostatin 1 and 26-succinylbryostatin 1 to in- 
hibit the binding of [3H]PDBu to this PKC fragment, the 
GST-Cys2 was first purified on glutathione beads, and 
then the protein was eluted with three volumes of 0.3 ml of 
5 mM glutathione, 50 mM Hepes, pH 8.0, and 10% 
ethylene glycol. The eluted protein was combined, and the 
assay was carried out as previously described [16,17]. The 
assay mixture (100 Ixl) contained 2 mM CaC12, 40 l~g/ml 
of sonicated phosphatidylserine (Avanti Polar Lipids, 
Birmingham, AL), 40 txl GST-Cys2 (approx. 20 p~g), 
Hepes 20 mM, pH 7.8, 154 nM [3H]PDBu, and bryostatin 
1 or 26-succinylbryostatin 1 diluted in 100% DMSO. The 
reaction mixture was incubated for 10 min at room temp. 
The binding reaction was stopped by the addition of 
ice-cold buffer (20 mM Tris-HCL, pH 7.5, 200 p~M CaCI 2, 
in 20% methanol). The mixture was filtered over glass 
fiber filters which were then washed with 10 ml of stop 
buffer. The filters were then counted in a scintillation 
counter. 
2.4. lmmunoprecipitation 
U937 cells were labelled with 0.1 mCi /ml  of 
[35S]methionine in miminal essential medium contianing 
10% (v /v)  dialyzed bovine calf serum lacking methionine. 
Native lysates were prepared by lysis in radioimmunopre- 
cipitation assay (RIPA) buffer [39]. Lysates were clarified 
by centrifugation, and the supernatant was precleared twice 
with protein A-sepharose beads, c-Jun was immunoprecip- 
itated with rabbit antisera t 1:500 dilution. Immune com- 
plexes were collected with protein A-sepharose beads, 
washed extensively, and resolved on SDS, 10% polyacryl- 
amide gels. 
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2.5. CAT assay 
U937 cells in the logarithmic phase of growth were 
transfected by electroporation [18]. CAT assays were per- 
formed as described [19]. 48 h after treatment, cells were 
pelleted, washed twice with Dulbecco's phosphate-buffered 
saline, and suspended in 100 ~1 of a buffer containing 250 
mM Tris-HCL, pH 7.8, 1 mM EDTA, 1 mM EGTA, and 2 
p~g aprotinin. Cells were freeze-thawed six times, and the 
homogenate was spun for 10 min in a microcentrifuge. The 
supernatant was removed, and the protein content was 
determined. 
The amount of protein used in the CAT assay was 
normalized by cotransfecting 5.0 p,g of a plasmid contain- 
ing [3-galactosidase was assayed using a reaction mixture 
containing 30 p~g (1 Ixg/~)), 3 I-tl magnesium buffer (1 p,l 
1.0 M MgC12, 350 p~l [3-mercaptoethan ol, 550 Ixl water), 
66 txl O-nitrophenyl-13-o-galactopyranoside (4 mg/ml dis- 
solved in sodium phosphate buffer, pH 7.5). The mixture 
was incubated at 37°C for 30 min-24 h until light yellow 
color developed. The reaction was stopped with 500 p,1 of 
NaCO 3 and absorbance measured at 410 nm. 
Protein from each time point was added to 200-pA 
reaction containing 250 mM Tris-HCL, pH 7.8, 0.5 mM 
acetylCoA, and [14 C]chloramphenicol (0.25 uCi). The 
reaction mixture was incubated for 1 h at 37°C and then 
extracted with 1 ml of ethyl acetate. The majority of the 
ethyl acetate was removed by centrifugation under vac- 
uum, and the remaining material was spotted onto a silica 
thin layer plate. After chromatography  in 
chloroform/methanol (95:1), the plate was dried, and 
autoradiography was done for 24 h. 
2.6. Platelet function 
Human platelet-rich plasma was incubated with varied 
amounts of bryostatin 1 or 26-succinylbryostatin 1, and 
lumiaggregometry [20,21] was performed. Aggregation of 
platelets is measured by the ability of platelets to scatter 
light. Absorbance is plotted over time on the Y-axis fol- 
lowing the addition of the agonist. 
2.7. Animal studies 
The melanoma tumor cell line K1735 M2 clone I0 was 
provided by Dr. Isaiah J. Fidler (Department of Cell 
Biology, M.D. Anderson Cancer Center, Houston, TX) and 
maintained in RPMI, 5% fetal bovine serum, L-glutamine, 
2 mM, non-essential mino acids, 100 p~M, sodium pyru- 
vate, 1 mM, and antibiotics. Prior to injection into the 
mice, cells were trypsinized and washed 3 times with PBS; 
then the tumors were established by the injection of 1 X 10 6 
cells/0.2 ml PBS into the tail vein. C3H/Hen mice were 
obtained from the Charles River Laboratories (Raleigh, 
NC). Three days after tumor injection, mice were begun on 
daily i.p. (1 p.g/mouse of either bryostatin 1 or 26-suc- 
cinylbryostatin 1) injections of different bryostatins in 0.2 
ml of 10% DMSO/PBS for a total of 15 days. On day 18 
after the injection of tumor cells, the animals were weighed, 
the lungs removed, and the left lung weighed. A section of 
the right lung was examined pathologically to document 
that the animal had been successfully engrafted with tumor 
cells. 
2.8. Synthesis of  26-succinylbryostatin 1 
To a solution of bryostatin 1 (23 mg, 25.4 txmol) in 
CH2C12 (1.0 ml) was added succinic anhydride (3.8 mg, 
38 txmol, 1.5 equiv.) and dimethylaminopyridine (4.6 mg, 
38 ~mol, 1.5 equiv.). After stirring at ambient temperature 
for 18 h, the solvent was evaporated. The residue was 
purified by centrifugal thin layer chromatography on silica 
gel (5% CH3OH/CH2C12 /E 100% CH3OH) to yield 23.7 
mg (78%). The synthesis of the triethanolammonium bryo- 
statin 1 26-succinate was accomplished by dissolving 0.53 
mg (0.53 ixmol) 26-succinylbryostatin 1 i 1.0 ml ethanol 
and adding 75 Ixl of an ethanol solution of triethaolamine 
(1.05 mg/ml, 0.079 mg, 0.53 Ixmol). 
The structure of the compound was verified by NMR 
spectroscopy on a GE Omega 500 MHz spectrometer. 
Spectra were obtained in CD2C12, and chemical shifts were 
assigned by 1H-COSY (two dimensional proton-proton 
COrrelated SpectroscopY) and IH-13C HMQC (Hetero- 
nuclear Multiple Quantum Coherence) NMR experiments 
and comparison to published spectra [22]. After stirring at 
ambient emperature for 10 min the solvent was evapo- 
rated to yield a white solid residue. 
To determine the relative solubilities of bryostatin 1and 
26-succinylbryostatin l triethanolamine salt, each com- 
pound (0.53-0.55 Ixmol) in a methanol stock solution was 
added to separate 10 ml pear flasks, and solvent was 
evaporated under reduced pressure [23]. To each flask was 
added 1.5 ml of 1-octanol-saturated water, followed imme- 
diately by addition of 1.5 ml water-saturated 1-octanol. 
The biphasic solutions were mixed vigorously with a 
Teflon stir vane for 10 min at ambient emperature (~ 
23°C), and the solutions were transferred to 15 ml 
polypropylene tubes and centrigued at 1600 X g for 15 
min. The 1- octanol and water layers were assayed for 
absorbance at 263 nm using a Beckman DU-7 spectro- 
photometer. Bryostatin concentrations were calculated us- 
ing a molar extinction coefficient (IE263) of 28700 for 
bryostatin 1 and 26-succinylbryostatin 1 triethanolamine 
salt [1]. 
3. Results 
Using the method escribed above, the logarithm of the 
partition coefficient (log P) was found to be 2.88 for 
bryostatin 1, compared to 0.88 for the triethanolamine salt 
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of 26-succinyl bryostatin l, indicating that the modified 
bryostatin 1 is 100-fold more water soluble than the parent 
compound. 
Homogenates of U937 cells were used as a source of 
PKC to evaluate the ability of 26-succinylbryostatin-1 to 
activate PKC in vitro. The PKC assay was carried out in 
the presence of 6 txg/ml of phosphatidylserine and 1 mM 
CaC12 using histone Ills as a phosphotransferase cceptor. 
In the absence of added bryostatins approximately 80 
cpm/l~g of cellular homogenate used as a source of 
enzyme were incorporated into the substrate (Fig. 1). The 
addition of either 26-succinylbryostatin l or bryostatin 1 
stimulated a concentration-dependent increase in PKC ac- 
tivity. Between 1-100 nM, bryostatin 1 stimulated a sig- 
nificantly greater PKC activity than identical concentra- 
tions of 26-succinylbryostatin 1 (Fig. 1). However, at the 
maximal concentration tested, 1000 nM, there was no 
difference in the ability of these compounds to stimulate 
PKC activity in vitro (Fig. 1). 
A competition assay was devised to examine the ability 
of 26- succinylbryostatin 1 to bind to PKC. Amino acids 
72-173 of PKC~/ bind phorbol esters. This short segment 
of the protein was expressed in bacteria s a fusion protein 
with glutathione S-transferase (GST) [ 16,17]. After expres- 
sion, this fusion protein was purified from the bacterial 
homogenate by binding to glutathione-Sepharose beads, 
followed by elution with glutathione. Since the bryostatins 
and phorbol esters bind to similar, if not identical, sites on 
PKC, the ability of varied concentrations of 26-suc- 
cinylbryostatin 1 or bryostatin l to bind to PKC could be 
measured by the displacement of [3H]phorbol dibutyrate 
([3H]PDBu) from the GST-PKC fusion protein. Both bryo- 
statin 1 and 26-succinylbryostatin 1 stimulated a dose-de- 
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Fig. 2. Displacement of [3H]PDBu from PKC by 26-succinylbryostatin 1. 
Varying concentrations of either 26- succinylbryostatin 1 or bryostatin 1
were added to a reaction containing GST-Cys2 (92-173), CaC12, and 
phosphatidylserine for 10 min at room temperature. The reaction was 
diluted with buffer (see Section 2) and filtered. The reaction was done in 
triplicate, and the average of duplicate xperiments a  well as the S.E. is 
shown. 
pendent decrease in the ability of [3H]PDBu to bind to the 
GST-PKC protein (Fig. 2). However, at each concentration 
tested bryostatin 1 displaced more [3H]PDBu than 26-suc- 
cinylbryostatin 1 (Fig. 2). At 1000 nM bryostatin 1 com- 
peted for all of the sites to the [3H]PDBu was bound; 
whereas, at the identical concentration of 26-suc- 
cinylbryostatin 1 only approximately 35% of the [3H]PDBu 
was displaced (Fig. 2). 
To examine whether 26-succinylbryostatin 1 was able 
to cross the cell membrane and act as a biologic effector in 
vivo, the effect of 26-succinylbryostatin 1 on U937 human 
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Fig. l. Activation of PKC by 26-succinylbryostatin 1. U937 cells were 
lysed and the homogenate ultracentrifuged for 30 min at 200000 X g. The 
supernatant was used as a source of PKC. Varying concentrations of
26-succinylbryostatin 1 (light bars) or bryostatin 1(dark bars) were added 
to the reaction (see Section 2) which contained 6 ~g/ml  of phosphatidyl- 
serine (Avanti) and no diacylglycerol. After 5 min the reaction was 
stopped and filtered. The reaction was done in triplicate and the average 
of duplicate xperiments a  well as the S.E. is shown. 
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Fig. 3. Cytosolic PKC activity after treatment of U937 cells with 26-suc- 
cinylbryostatin 1.U937 cells (1.0.107) were treated with various concen- 
trations of bryostatin 1 (light line) or 26-succinylbryostatin 1 (dark line) 
for 1 h. The cells were, pelleted washed, homogenized, and centrifuged at 
200000X g for 30 rain. 40 p,g of cytosolic protein were assayed for 5 
min as described in Section 2. The results are the average of three 
experiments done in triplicate, and the S.E. of these measurements is 
shown. 
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leukemic ells was examined. The addition of bryostatin 1
to U937 human leukemic ells stimulates the translocation 
of PKC from the cytosol to the membrane. This transloca- 
tion causes a drop in measurable cytosolic PKC activity 
and an increased association with the plasma membrane. 
To determine whether 26-succinylbryostatin 1 is able to 
affect the cytosolic activity of PKC, U937 cells were 
treated with varying doses of either bryostatin 1 or 26-suc- 
cinylbryostatin 1 for 1 h. The cells were then broken open 
and the cytosolic fraction separated from membranes by 
ultracentrifugation. The cytosolic PKC activity was then 
measured. The addition of bryostatin 1 to these cells 
stimulated a concentration-dependent decrease in the cy- 
tosolic PKC activity (Fig. 3). In contrast, given the vari- 
ability of the assay, no significant change in the cytosolic 
activity of PKC was seen after treatment with 26-suc- 
cinylbryostatin 1.To examine whether succinylbryostatin 1 
stimulated tranlocation of PKC to the particulate fraction, 
the cell pellet was extracted with Triton X-100 and the 
PKC activity measured in both fractions (Fig. 4A). In a 
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Fig. 4. Membrane association of PKC in bryostatin 1 and 26-succinylbryostatin 1 treated cells. (a) PKC activity in the cytosol (C) and pellet (P). 5 • 107 
U937 cells were treated with either DMSO (control), 26 succinylbryostatin I (0.1 IxM), or bryostatin 1(0.1 I~M) for 30 rain. The cytosolic and membrane 
bound forms were assayed as described in Sections 2. The experiment was done in duplicate with each point r~ ing  the average of 6 values. The 
standard eviation of these values for the cytosol (C), pellet (P) and total (T) is shown. (b) PKC western blot of U937 cells. 2.107 U937 cells were treated 
with bryostatin 1, 26-succinylbryostatin 1 or vehicle for 30 rain. The amount of PKC g in the cytosol (C) and pellet (P) fractions was evaluated by western 
blot as described in Section 2. The molecular weight (M.W.) standards are shown in kDa. 
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Fig. 5. 26-Succinylbryostatin 1 stimulates c-Jun phosphorylation. 1.107 
U937 cells were labelled with [35S]methionine (100 ~Ci/ml) for 4 h 
followed by treatment with 1 ~M 26-succinylbryostatin 1 (SB) or bryo- 
statin 1 (B) for 30 min. The cells were then pelleted and homogenized, 
and c-Jun immunoprecipitation wascarried out [18]. The arrows denote 
bands which are retarded secondary tophosphorylation. 
separate xperiment, the pellet (P) and cytosol (C) frac- 
tions from bryostatin 1 and 26-succinylbryostatin 1 treated 
U937 cells were run on an SDS-PAGE and Western 
blotted with an antibody specific for PKC delta (8) (Fig. 
4B). In both assays bryostatin 1 translocated PKC to the 
membrane while 26-succinylbryostatin 1 did not as evi- 
denced by modulation of enzyme activity and PKC 
location. These data could be interpreted to mean that 
because of increased water solubility, 26-succinylbryosta- 
tin 1 did not enter the cell; or, that because of decreased 
lipid solubility of 26-succinylbryostatin 1, no or little 
stimulation of PKC translocation took place. 
To evaluate further whether 26-succinylbryostatin 1 had 
any biologic effects on these cells, the ability of this 
compound to stimulate the phosphorylation of c-Jun pro- 
tein was evaluated, c-Jun is a protein which is capable of 
dimerizing through its leucine zipper [24]. As a homodimer 
or a heterodimer with the c-fos protein, it binds to DNA 
upstream of the start site of transcription and acts to 
enhance transcription [25]. The addition of PKC activators, 
including phorbol esters and bryostatin 1, to U937 cells 
stimulates the activity of a protein kinase which phospho- 
rylates the c-Jun (identified as c-JATPK [26], JNK [27], 
SAPK [28]). Phosphorylation o  a number of serines causes 
the c-Jun protein to migrate more slowly upon SDS-PAGE 
electrophoresis giving the formation of 3 retarded bands 
[18]. To examine the ability of 26-succinylbryostatin 1 to 
stimulate phosphorylation of c-Jun, U937 cells were la- 
belled with [35S]methionine and then treated for 30 min 
with either 1000 nM 26-succinylbryostatin 1 or bryostatin 
1, and the c-Jun was then immunoprecipitated. The im- 
munoprecipitate was run on an SDS-PAGE, and the gel 
was dried and flurographed (Fig. 5). Both bryostatin 1 and 
26-succinylbryostatin I stimulated phosphorylation of c- 
Jun, as demonstrated by the retarded mobility of c-Jun 
bands. 
To establish a dose-response curve for the biologic 
effects of 26-succinylbryostatin 1, the effect of this com- 
pound on AP-1 mediated transcription was evaluated, c-Jun 
as a homodimer or a heterodimer with members of the Fos 
family of proteins binds to the DNA sequence 5'- 
TCAGTCA-3'  [29]. Phosphorylation of c-Jun enhances 
transcription from this DNA sequence [ 18]. To evaluate the 
ability of 26-succinylbryostatin 1 to stimulate transcription 
from this sequence, U937 cells were transfected with a 
cDNA containing five copies of the AP-I enhancer up- 
stream of a chloroamphemicol acetyltransferase (CAT) 
reporter gene. These cells were then treated for 72 h with 
varying concentrations of either 26-succinylbryostatin 1 or 
treatment Con bryostat in 1 
molar i ty  (nM) 1000 100 10 
SUccinvlbryostatin 1 
10o0 lOO 10 
Fold 
2.51 3.08 3.09 3A 7 2.47 1.13 
Act ivat ion  
Fig. 6. 26-Succinylbryostatin stimulates 5 X -AP-1 activity. 7 • 10  7 U937 cells were electroporated with 70 ~g of 5 X -AP-1 CAT cDNA (19). 24 h later 
the cells were divided (1 • 107cells/aliquot) and each aliquot was treated for 72 h with various concentrations of 26-succinylbryostatin 1 a d bryostatin 1.
At the end of 72 h the cells were homogenized, and CAT assays were performed as described in Section 2. The modified chloramphenicol was scraped 
from the TLC plate and counted. The fold-activation is calculated by dividing the control value into those from bryostatin-treated c lls. 
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Fig. 7. Lack of platelet aggregation after treatment with 26-succinylbryostatin 1. Human platelet-rich plasma was incubated with varied concentrations of
26-succinylbryostatin 1 and bryostatin 1. The aggregation of platelets is measured by the ability of platelets to scatter light. Absorbance is plotted over time 
on the Y-axis following the addition of the agonist. 
bryostatin 1 (Fig. 6). The cells were then lysed, a [3- 
galactosidase assay done to control fo~" transfection effi- 
ciency, and the CAT activity was measured. The addition 
of 1000 nM 26-succinylbryostatin 1 and bryostatin 1 stim- 
ulated 5 × -AP-1 enhancer activity (Fig. 6). There was a 
dose-response r lationship for the CAT activity stimulated 
by 26-succinylbryostatin 1 with 10 nM showing little 
stimulation above background. In contrast, even at 10 nM, 
bryostatin 1 was still actiw~ at stimulated 5 × -AP-1 activ- 
ity (Fig. 6). Together the results on c-Jun phosphorylation 
and 5 ×-AP-1 driven CAT activity suggest hat 26-suc- 
cinylbryostatin 1 is capable of entering cells and stimulat- 
ing biologic events. 
The addition of bryostatin 1 to U937 cells induces an 
inhibition of cell growth and differentiation of these cells 
to monocyte/macrophages as evidenced by the induction 
of monocyte specific enzymes [40]. To evaluate the effect 
of 26-succinylbryostatin 1, U937 cells were grown in the 
presence of this compound for 96 h. Cell growth was 
measured and cells were ,;mined for cx-napthylesterase, a 
marker of monocyte/macrophage differentiation. 1 IxM 
26-succinylbryostatin 1 induced a 60% inhibition of cell 
growth (average of triplicate determinations in two experi- 
ments), whereas the 0.1 IxM treatment caused a 20% 
inhibition of cell growth and 0.01 IxM had no effect. The 
induction of a-napthylesterase paralleled the inhibition of 
cell growth with 66% of cells staining enzyme positive 
after treatment with 1 IxM 26-succinylbryostatin 1. Thus, 
the concentrations of 26-succinylbryostatin 1 which acti- 
vate gene transcription also inhibit cell growth and induce 
increases in an enzyme found in differentiated leukemic 
cells. 
When blood is drawn from mice injected i.v. with 
bryostatin 1 the platelets contained in these blood samples 
cannot be activated [30]. This inability to activate the 
platelets is secondary to the bryostatin 1-induced activation 
which occurs in vivo. Also, in vitro the addition of bryo- 
statin 1 directly to human platelets causes the aggregation 
of these platelets, making them no longer responsive to 
additional stimuli [30]. To examine the effect of 26-suc- 
cinylbryostatin 1 on human platelets, varying doses of this 
compound were added directly to human platelets, which 
were then subjected to lumiaggregometry. Aggregation of 
the platelets is evident after addition of 1000 and 100 nM 
Table 1 
The effect of bryostatin 1 and 26-succinylbryostatin 1 on tumor regres- 
sion and weight loss 
Control a Bryostatin 1 Succinyl- Uninjected 
(n = 10) treatment ~ brostatin c (n = 8) 
(n = 10) (n = lO) 
Lung 
weights 
(g) 
0.327 + .045 d 0.205_+.025 e 0.262_+.041 f 0.07+0.006 
a Mice were injected with 106 melanoma cells received no treatment and 
were sacrificed on day 18. 
b Mice were injected with melanoma ceils plus 1 tzg bryostatin 1 i.p. 
from day 3-17. 
c Mice were treated with melanoma cells plus 1 ~g of 26-suc- 
cinylbryostatin 1 i.p. from day 3-17. 
J Values shown are the mean + S.E. 
e Different from control at P < 0.0327. 
f Different from control at P < 0.2408. 
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600 c ~ COO® + 
Fig. 8. A potential mechanism for intramolecular hydrolysis of 26-succinylbryostatin 1. A potential mechanism for the intramolecular hydrolysis of 
26-succinylbryostatin 1 s diagramed. 
bryostatin 1but is not apparent after treatment with similar 
doses of 26-succinylbryostatin 1 (Fig. 7). Although there 
are biologic effects of these doses in human cells in 
culture, no significant aggregation of human platelets was 
evident. 
Bryostatin 1 injection into mice previously injected 
intravenously with B I6 melanoma both decreases the 
growth of pulmonary melanoma nd prolongs the life of 
the mice [7,31]. This decrease in tumor growth in the lungs 
correlates directly with post-mortem lung weight. To eval- 
uate whether 26-succinylbryostatin 1 could act as an anti- 
cancer compound, mice were injected intravenously with 
B16 melanoma cells. Three days later the mice were 
injected intraperitoneally with 1 ixg bryostatin 1or 26-suc- 
cinylbryostatin 1, and these injections were continued aily 
for 15 days. The bryostatin 1 dose was chosen, because 
when given at higher doses on a daily basis bryostatin 1
can be lethal (data not shown). After treatment was con- 
cluded, the mice were then sacrificed, and the lung weights 
were recorded. Because melanoma growth was localized in 
the lung, measurement of the weight of this tissue was 
chosen as an endpoint rather than animal mortality. As 
reported previously [7,31], bryostatin 1 signficantly inhib- 
ited the growth of the melanoma in the lungs when com- 
pared to untreated tumor bearing animals (Table 1). While 
the 26-succinylbryostatin 1 injected animals showed de- 
creased lung weights, when the variability among the 
animals was taken into account the decrease in lung weights 
was not significant (Table 1). The lung weights for bryo- 
statin 1 injected animals were significantly different from 
uninjected animals, suggesting that although bryostatin 1 
inhibited tumor growth it did not completely irradicate the 
melanoma cells. 
4. Discussion 
A significant number of patient side effects have been 
caused by the vehicle in which bryostatin 1 is adminis- 
tered. Thus, modifications of the bryostatin 1 ring might 
increase the solubility of this compound in aqueous olu- 
tions and allow this modified bryostatin to be administered 
in physiologic solutions. The bryostatin 1 molecule dis- 
plays a limited number of functional groups which might 
be utilized for preparing prodrug derivatives. The C-26 
alcohol moiety, however, may be readily esterified [32]. 
Alcohol moieties have often been derivatized with succi- 
hate esters to increase the water solubility of lipophilic 
drugs [33]. For example, the free acid of 2'-succinyl taxol 
was prepared [34], but this compound had disappointing in
vivo activity against P388 leukemia cells when compared 
to taxol [7]. Interestingly the antitumor activity of 2'-suc- 
cinyl taxol against B-I 6 melanoma xenografts was partly 
dependent on the counterion employed [35]. The 2'-suc- 
cinyl taxol triethanolamine salt was more active than the 
parent drug, taxol, and either the 2'-succinyl free acid or 
sodium salt derivatives. We have synthesized the tri- 
ethanolamine salt of 26-succinylbryostatin 1, and have 
evaluated its biological activity because of (1) its increased 
solubility in aqueous olutions, [2] its potential to undergo 
an intramolecular catalytic release of bryostatin 1(Fig. 8), 
and [3] the possibility that this agent could be acted upon 
by plasma or tissue esterases to liberate bryostatin 1. To 
examine the possibility that 26-succinylbryostatin 1 was 
cleaved or went through intramolecular catalytic release, 
26-succinylbryostatin 1 was incubated with U937 cells or 
alone in medium for 72 h. The presence of 26-suc- 
cinylbryostatin 1 breakdown products was then examined 
by HPLC followed by mass spectrometry. By this method, 
only 26-succinylbryostatin 1 and no altered compounds 
was found in the medium when incubated with or without 
cells. The levels of 26-succinylbryostatin 1 appeared 
grossly unchanged. Thus, although the chemical structure 
suggests the possibility of an intramolecular rearrange- 
ment, none could be detected in tissue culture. Insufficient 
amounts of compound were available to analyze structural 
changes in 26-succinylbryostatin 1 i mice. 
We have used a fusion protein expressing the phorbol 
ester-binding domain of PKC bound to GST to examine 
the ability of 26-succinylbryostatin 1 to bind to PKC. We 
find that even when 26-succinylbryostatin 1 is present in 
10-fold excess (1 I~M) of [3H]PDBu, it displaces only 
~ 30% of the PDBu, in comparison to bryostatin 1 dis- 
places 100%. The decreased binding of 26 substituted 
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bryostatins to PKC has been previously demonstrated [36]. 
Esterification of the 26 position of bryostatin 4 caused a 
dramatic decrease in affinity for PKC [36], suggesting that 
this position was important for PKC binding. This decrease 
in ability to bind PKC is reflected in the decreased ability 
of 26-succinylbryostatin 1 to stimulate PKC-mediated 
phosphorylation f the histone substrate (Fig. 1). In com- 
parison, when examining the bryostatin stimulation of 
PKC phosphorylation at the highest concentration tested (1 
~M), the activity of these two bryostatins differed little, 
suggesting that stimulation of PKC phosphorylation may 
be less sensitive to differences in these two compounds 
than PKC binding affinity. 
The addition of bryostatin 1 to both NIH-3T3 [37] and 
U937 cells causes translocation from the cytosol to the 
membrane of a number of the PKC isoforms. This translo- 
cation is associated with a drop in cytosolic PKC. How- 
ever, in comparison to bryostatin 1, 26-succinylbryostatin 
1 did not stimulate significant loss of cytosolic PKC 
activity nor association with the membrane. Western blot 
using an antibody to PKC B, a novel PKC isoform, also 
did not disclose any translocation. A longer incubation (4 
h) with 26-succinylbryostatin 1 gave identical results, sug- 
gesting that more prolonged exposure did not increase the 
amount of this compound that entered the cell. These 
findings could result from either 26-succinylbryostatin 1 
not entering the cell or, because of its decreased lipid 
solubility, not binding PKC on the membrane. 
Because PKC can be activated by bryostatin 1 in the 
absence of membrane translocation [38], it was possible 
that 1 I~M 26-succinylbryostatin 1 stimulated PKC in cells 
without significant membrane translocation. To evaluate 
this possibility both the phosphorylation f c-Jun protein 
and the activation of transcription by this protein were 
measured. Like bryostatin 1, 26-succinylbryostatin 1, 1000 
and 100 nM stimulated own-stream protein kinases to 
phosphorylate c-Jun and the activation of transcription 
from a 5 × AP-1 enhancer element. The biological activity 
of 10 nM 26-succinylbryostatin 1 was not markedly differ- 
ent from control untreated cells. Measurements of growth 
suggest that concentrations that have an effect on transcrip- 
tion also inhibit cell growth, suggesting that at these doses 
26-succinylbryostatin 1 has biologic activity in tissue cul- 
ture. 
A potential major side effect of bryostatin 1 is platelet 
activation. In human trials a drop in platelet count has been 
seen but no obvious bleeding was apparent [11,15]. Higher 
doses of bryostatin 1 have been shown to activate the 
aggregation of human platelets in vitro [30]. However, in 
comparison to bryostatin 1, 26-succinylbryostatin 1 did not 
stimulate any changes in platelet function. It is possible 
that 26-succinylbryostatin 1 was not sufficiently lipid solu- 
ble to enter the platelet or that PKC translocation was 
necessary for platelet aggregation. 
Murine B16 melanoma when injected intravenously 
forms pulmonary colonies that have has proven responsive 
to bryostatin 1 [7,31]. After 26-succinylbryostatin 1 i jec- 
tion, although there was a trend towards inhibition of 
melanoma growth in the lungs with lower lung weights 
than controls (0.262 vs. 0.327), this effect was not statisti- 
cally significant when the variability of the weights was 
taken into account. It is possible that the high lipid solubil- 
ity of bryostatin 1 while making it difficult to administer 
the compound is necessary for the antitumor effects of this 
compound. Also, it is possible that the acqueous olubility 
of 26-succinylbryostatin 1 could lead to the rapid excretion 
of this compound. 
Our work suggests that 26-succinylbryostatin 1 does not 
bind as tightly to PKC as PDBu but is capable of activat- 
ing PKC to phosphorylate histone. In tissue culture 26-suc- 
cinylbryostatin 1 stimulates the phosphorylation f specific 
proteins without marked transloeation of PKC to the mem- 
brane and inhibits the growth of leukemic ells. Since it is 
unknown how bryostatins inhibit tumor growth, the impor- 
tance of these in vitro observation to the mouse melanoma 
model is unclear. Further testing of modified bryostatins 
with higher aqueous olubility combined with the potential 
to break down to bryostatin 1 in vivo seems warranted to 
develop better chemotherapeutic agents and to clarify 
whether lipid solubility is necessary for chemotherapeutic 
effect. 
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